Indocyanine Green Patent Expiration
Indocyanine Green is used for visualizing blood flow in various surgical procedures and organ transplants. It was first introduced by Renew Pharmaceuticals Ltd
Indocyanine Green Patents
Given below is the list of patents protecting Indocyanine Green, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Spy Agent Green Kit | US11712320 | Methods and systems to automate surgical interventions | Jul 14, 2039 | Novadaq Tech |
| Spy Agent Green Kit | US10631746 | Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography | Aug 04, 2035 | Novadaq Tech |
| Spy Agent Green Kit | US8406860 | Method for evaluating blush in myocardial tissue | Apr 09, 2029 | Novadaq Tech |
| Spy Agent Green Kit | US8647605 | Real time imaging during solid organ transplant | Feb 11, 2029 | Novadaq Tech |
| Spy Agent Green Kit | US8185176 | Method and apparatus for vasculature visualization with applications in neurosurgery and neurology | Jun 04, 2028 | Novadaq Tech |
| Spy Agent Green Kit | US9421280 | Real time imaging during solid organ transplant |
Nov 24, 2025
(Expired) | Novadaq Tech |
| Spy Agent Green Kit | US7881777 | Method and apparatus for performing intra-operative angiography |
Sep 22, 2021
(Expired) | Novadaq Tech |
| Spy Agent Green Kit | US6915154 | Method and apparatus for performing intra-operative angiography |
Aug 01, 2021
(Expired) | Novadaq Tech |
| Spy Agent Green Kit | US8892190 | Method and apparatus for performing intra-operative angiography |
Aug 11, 2020
(Expired) | Novadaq Tech |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Indocyanine Green's patents.
Latest Legal Activities on Indocyanine Green's Patents
Given below is the list recent legal activities going on the following patents of Indocyanine Green.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Sep, 2024 | US8406860 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Feb, 2024 | US9421280 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Oct, 2023 | US10631746 |
| Recordation of Patent eGrant | 01 Aug, 2023 | US11712320 |
| Mail Patent eGrant Notification | 01 Aug, 2023 | US11712320 |
| Patent eGrant Notification | 01 Aug, 2023 | US11712320 |
| Patent Issue Date Used in PTA Calculation Critical
| 01 Aug, 2023 | US11712320 |
| Email Notification Critical
| 01 Aug, 2023 | US11712320 |
| Electronic Review Critical
| 01 Aug, 2023 | US11712320 |
| Recordation of Patent Grant Mailed Critical
| 01 Aug, 2023 | US11712320 |
Indocyanine Green's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Indocyanine Green:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
